The Ohio State University
Columbus, Ohio, 43210, United States
NCT Number: NCT05318183
This study will investigate the gut microbiota-mediated effects of whole wheat consumption on human health in adults with pre-diabetes. Participants will complete two phases of intervention in random order in which they will consume either whole wheat bread (4 servings) or white bread a day for two weeks prior to collecting specimens (stool, urine, and plasma/serum).
This study is active but is not currently recruiting participants.
18 year–65 year
All sexes
Interventional
Not applicable
Columbus, Ohio, 43210, United States
Accumulating clinical evidence suggests positive effects of whole grain on cardiometabolic risk. However, outcomes of controlled trials indicate that substantial interpersonal variation occurs in these studies with regard to glucose homeostasis, with some persons being unaffected and others experiencing glucose-lowering effects due to whole wheat bread consumption. Whole grain (whole wheat) contains bioactive phytochemicals in addition to its well-recognized fiber content, and these constituents have not received adequate study to inform dietary recommendations. The objective of this study is to investigate the glucose-lowering effects of whole wheat bread in persons with prediabetes using multi-omics platforms that can provide an understanding of the complex interactions among the gut microbiome, gut metabolome, host metabolome, and gut barrier function. The hypothesis is that gut microbial metabolism of whole wheat and its major bioactive components is a determining factor of human health benefits. This will be tested by conducting a randomized, controlled crossover trial in persons with pre-diabetes who follow a controlled diet containing whole wheat bread or white bread for 2-weeks. Outcomes are expected to significantly advance an understanding of personalized, gut microbiome-mediated approaches in individuals with pre-diabetes to help guide dietary recommendations of whole wheat intake. In addition, novel evidence that maps out the differential functions of diverse genus/species of microbiota to biotransform whole wheat nutrients into more bioactive metabolites are expected.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Standardized whole wheat bread (128 g daily)
Standardized white bread (128 g daily)
Time frame: Day 14 (0, 30, 60, 90, 120, 150, 180 minutes post oral glucose tolerance test)
Data are biomarker area under the time-concentration curve (0-3 hours) on day 14
Time frame: Day 14
Data are biomarker fasting concentrations
Time frame: Day 14
Data are biomarker fasting concentrations.
Time frame: Day 14
Data are the biomarker serum concentration of C-reactive protein.
Time frame: Day 14
Data are biomarker serum tumor necrosis factor alpha concentrations.
Time frame: Day 14
Data are biomarker serum interleukin-6 concentrations.
Time frame: Day 14
Data are biomarker fecal concentrations.
Time frame: Day 14
Data are biomarker fecal concentrations.
Time frame: Day 14
Data are the 24-hour urinary excretion ratio of lactulose relative to mannitol collected 0-5 h following the digestion of non-digestible sugar probes.
Time frame: Day 14
Data are the sucralose/erythritol ratio measured in urine collected 6-24 h following the digestion of non-digestible sugar probes.
Time frame: Day 14
Data are biomarker fasting concentrations.
Time frame: Day 14
Data are biomarker serum concentrations.
Time frame: Day 14
Data are expression of toll-like receptor 4 gene from peripheral blood mononuclear cells.
Time frame: Day 14
Expression of myeloid differentiation factor 88 gene from peripheral blood mononuclear cells.
Time frame: Day 14
Expression of tumor necrosis factor alpha gene from peripheral blood mononuclear cells.
Time frame: Day 14
Expression of p65 subunit of nuclear factor kappa B gene from peripheral blood mononuclear cells.
Time frame: Day 14
Expression of interleukin-6 gene from peripheral blood mononuclear cells.
Time frame: Day 14
Expression of interleukin-8 gene from peripheral blood mononuclear cells.
Time frame: Day 14
Expression of myeloperoxidase gene from peripheral blood mononuclear cells.
Time frame: Day 14
Expression of monocyte chemoattractant protein-1 gene from peripheral blood mononuclear cells.
Time frame: Day 14
Data are biomarker fecal concentrations.
Time frame: Day 14
Data are biomarker fecal concentrations.
Time frame: Day 14
Data are biomarker fecal concentrations.
Time frame: Day 14
Data are biomarker fecal concentrations.
Time frame: Day 14
Data are biomarker fecal concentrations of isovaleric acid.
Time frame: Day 14
Data are biomarker serum concentrations of alkylresorcinol and alkylresorcinol derivatives.
Time frame: Day 14
Data are biomarker serum concentrations of benoxazinoids and benoxazinoids derivatives.
Time frame: Day 14
Data are biomarker serum concentrations of phenolic compounds and phenolic derivatives.
Time frame: Day 14
Data are biomarker fecal concentrations of alkylresorcinols and alkylresorcinol derivatives.
Time frame: Day 14
Data are biomarker fecal concentrations of benoxazinoids and benoxazinoids derivatives.
Time frame: Day 14
Data are fecal concentrations of phenolic compounds and phenolic derivatives.
Time frame: Day 0, Day 14
Data are biomarker fasting plasma concentrations.
Time frame: Day 14
Data are biomarker fasting plasma concentrations.
Time frame: Day 14
Data are biomarker fasting plasma concentrations.
Time frame: Day 14
Data are biomarker serum concentrations of alanine transaminase.
Time frame: Day 14
Data are biomarker serum interleukin-8 concentrations.
Time frame: Day 14
Alpha-diversity will be determined based on the Shannon-Wiener diversity index. Fecal microbiota assessments and the subsequent determinations of alpha-diversity.
Time frame: Day 14
Beta-diversity will be determined based on the Bray-Curtis diversity index. Fecal microbiota assessments and the subsequent determinations of beta-diversity.
Time frame: Day 14
Gut microbiota relative abundance (percent order, genus, and species level) will be measured in fecal samples.
Ohio State University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02037321
Arthritis, Body Weight
Toronto, Ontario, Canada
View Trial DetailsNCT07144670
Adipose Tissue, Adipose Tissue Inflammation
Svendborg, Denmark
View Trial DetailsNCT04031222
Adolescent Obesity, Beta Cell Dysfunction
Toronto, Ontario, Canada
View Trial DetailsNCT01765946
Aging, Diabetes Mellitus
Padova, Italy
View Trial Details